Paying users zone. Data is covered by 
.
Get 1 month access to Johnson & Johnson for $19.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Johnson & Johnson (JNJ)
Long-term Debt and Solvency Analysis
Difficulty: Beginner
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Ratios (Summary)
Johnson & Johnson, debt and solvency ratios
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Debt Ratios | ||||||
| Debt to equity | |
|
|
|
|
|
| Debt to capital | |
|
|
|
|
|
| Debt to assets | |
|
|
|
|
|
| Financial leverage | |
|
|
|
|
|
| Coverage Ratios | ||||||
| Interest coverage | |
|
|
|
|
|
| Fixed charge coverage | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
| Ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Johnson & Johnson’s debt to equity ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Johnson & Johnson’s debt to capital ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Johnson & Johnson’s debt to assets ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Johnson & Johnson’s financial leverage ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
| Ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Johnson & Johnson’s interest coverage ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Johnson & Johnson’s fixed charge coverage ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
Debt to Equity
Johnson & Johnson, debt to equity calculation, comparison to benchmarks
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Loans and notes payable | |
|
|
|
|
|
| Long-term debt, excluding current portion | |
|
|
|
|
|
| Total debt | |
|
|
|
|
|
| Shareholders’ equity | |
|
|
|
|
|
| Ratio | ||||||
| Debt to equity1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Debt to Equity, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Debt to Equity, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
1 2018 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Johnson & Johnson’s debt to equity ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Debt to Capital
Johnson & Johnson, debt to capital calculation, comparison to benchmarks
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Loans and notes payable | |
|
|
|
|
|
| Long-term debt, excluding current portion | |
|
|
|
|
|
| Total debt | |
|
|
|
|
|
| Shareholders’ equity | |
|
|
|
|
|
| Total capital | |
|
|
|
|
|
| Ratio | ||||||
| Debt to capital1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Debt to Capital, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Debt to Capital, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
1 2018 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Johnson & Johnson’s debt to capital ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Debt to Assets
Johnson & Johnson, debt to assets calculation, comparison to benchmarks
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Loans and notes payable | |
|
|
|
|
|
| Long-term debt, excluding current portion | |
|
|
|
|
|
| Total debt | |
|
|
|
|
|
| Total assets | |
|
|
|
|
|
| Ratio | ||||||
| Debt to assets1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Debt to Assets, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Debt to Assets, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
1 2018 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Johnson & Johnson’s debt to assets ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Financial Leverage
Johnson & Johnson, financial leverage calculation, comparison to benchmarks
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Total assets | |
|
|
|
|
|
| Shareholders’ equity | |
|
|
|
|
|
| Ratio | ||||||
| Financial leverage1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Financial Leverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Financial Leverage, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
1 2018 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Johnson & Johnson’s financial leverage ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Interest Coverage
Johnson & Johnson, interest coverage calculation, comparison to benchmarks
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Net earnings | |
|
|
|
|
|
| Add: Income tax expense | |
|
|
|
|
|
| Add: Interest expense, net of portion capitalized | |
|
|
|
|
|
| Earnings before interest and tax (EBIT) | |
|
|
|
|
|
| Ratio | ||||||
| Interest coverage1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Interest Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Interest Coverage, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
1 2018 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Johnson & Johnson’s interest coverage ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |
Fixed Charge Coverage
Johnson & Johnson, fixed charge coverage calculation, comparison to benchmarks
| Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 28, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Net earnings | |
|
|
|
|
|
| Add: Income tax expense | |
|
|
|
|
|
| Add: Interest expense, net of portion capitalized | |
|
|
|
|
|
| Earnings before interest and tax (EBIT) | |
|
|
|
|
|
| Add: Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases | |
|
|
|
|
|
| Earnings before fixed charges and tax | |
|
|
|
|
|
| Interest expense, net of portion capitalized | |
|
|
|
|
|
| Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases | |
|
|
|
|
|
| Fixed charges | |
|
|
|
|
|
| Ratio | ||||||
| Fixed charge coverage1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Fixed Charge Coverage, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-20), 10-K (filing date: 2018-02-21), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-24).
1 2018 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Johnson & Johnson’s fixed charge coverage ratio deteriorated from 2016 to 2017 and from 2017 to 2018. |